OPTHEA LTD Net Assets
OPTHEA LTD net assets. Based on the latest financial reports, OPTHEA LTD (UKJ) has net assets worth €-168.71 Million EUR (≈ $-197.23 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€145.77 Million ≈ $170.42 Million USD) and total liabilities (€314.48 Million ≈ $367.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of OPTHEA LTD to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-168.71 Million |
| % of Total Assets | -115.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of OPTHEA LTD (2022–2025)
Net assets of OPTHEA LTD from 2022 to 2025. This chart illustrates how OPTHEA LTD's net assets have evolved over time, based on quarterly financial data. See UKJ net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for OPTHEA LTD (2022–2025)
The table below shows the annual net assets of OPTHEA LTD from 2022 to 2025. For live market cap and overall valuation, see OPTHEA LTD stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €-201.07 Million ≈ $-235.07 Million |
-165.23% |
| 2024-06-30 | €-75.81 Million ≈ $-88.63 Million |
-1195.19% |
| 2023-06-30 | €-5.85 Million ≈ $-6.84 Million |
-112.20% |
| 2022-06-30 | €47.98 Million ≈ $56.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OPTHEA LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52555364700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
OPTHEA LTD Net Assets Breakdown (June 2025)
OPTHEA LTD net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €541.43 Million | % |
| Total Equity | €-201.07 Million | 100.00% |
OPTHEA LTD Competitors by Market Cap
The table below lists competitors of OPTHEA LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Palatin Technologies, Inc. Common Stock
NASDAQ:PTN
|
$8.90 Million |
|
Kolon Corp
KO:002025
|
$8.90 Million |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
$8.90 Million |
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
$8.90 Million |
|
In8bio Inc
NASDAQ:INAB
|
$8.89 Million |
|
CWG Holdings Bhd
KLSE:9423
|
$8.88 Million |
|
Nuchev Ltd
AU:NUC
|
$8.88 Million |
|
Spring Art Holdings Bhd
KLSE:0216
|
$8.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OPTHEA LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -75,810,000 to -201,069,000, a change of -125,259,000.
- Net loss of 162,791,000 reduced equity.
- New share issuances of 34,809,000 increased equity.
- Other factors increased equity by 2,723,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-162.79 Million | -80.96% |
| Share Issuances | €34.81 Million | +17.31% |
| Other Changes | €2.72 Million | +1.35% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares OPTHEA LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.12 | €0.01 | x |
| 2023-06-30 | €-0.01 | €0.01 | x |
| 2024-06-30 | €-0.07 | €0.01 | x |
| 2025-06-30 | €-0.16 | €0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OPTHEA LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -651164.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -193.46% | -102353.66% | 0.00x | 1.25x | €-97.62 Million |
| 2023 | 0.00% | -131963.89% | 0.00x | 0.00x | €-141.94 Million |
| 2024 | 0.00% | -176193.60% | 0.00x | 0.00x | €-212.66 Million |
| 2025 | 0.00% | -651164.00% | 0.00x | 0.00x | €-142.68 Million |
Industry Comparison
This section compares OPTHEA LTD's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $380,407,590
- Average return on equity (ROE) among peers: -34.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OPTHEA LTD (UKJ) | €-168.71 Million | -193.46% | N/A | $8.89 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-1.58 Million | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $144.67 Million |
| PreveCeutical Medical Inc (18H) | $-6.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $696.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About OPTHEA LTD
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macula… Read more